US Patent 9358304 Methods of making DLL3 antibody drug conjugates

Patent 9358304 was granted and assigned to Stemcentrx, Inc. on June, 2016 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

9358304

Date of Patent

June 7, 2016

Patent Application Number

15005993

Date Filed

January 25, 2016

Patent Citations Received

‌

US Patent 12084518 Trispecific binding proteins and methods of use

‌

US Patent 11976125 B cell maturation antigen binding proteins

Patent Primary Examiner

‌

Christine J. Saoud

Patent abstract

Novel modulatators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9358304 Methods of making DLL3 antibody drug conjugates

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API